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Background: Activation of extracellular signal-regulated kinase1/2 (ERK1/2) in dorsal horn of the spinal cord by
peripheral inflammation is contributed to inflammatory pain hypersensitivity. Although electroacupuncture (EA)
has been widely used to alleviate various kinds of pain, the underlying mechanism of EA analgesia requires further
investigation. This study investigated the relationship between EA-induced analgesia and ERK signaling involved in
pain hypersensitivity.
Methods: The rats were randomly divided into control, model, EA and sham EA groups. Inflammatory pain model
was induced by injecting of 100 μl Complete Freund’s adjuvant (CFA) into the plantar surface of a hind paw. Rats in
the EA group were treatment with EA (constant aquare wave, 2 Hz and 100 Hz alternating frequencies, intensities
ranging from 1-2 mA) at 5.5 h, 24.5 h and 48.5 h. Paw withdrawal thresholds (PWTs) were measured before modeling
and at 5 h, 6 h, 25 h and 49 h after CFA injection. Rats were killed and ipsilateral side of the lumbar spinal cords were
harvested for detecting the expressions of p-ERK1/2, Elk1, COX-2, NK-1 and CREB by immunohistochemistry, real-time
PCR, western blot analysis and EMSA. Finally, the analgesic effect of EA plus U0126, a MEK (ERK kinase) inhibitor, on CFA
rats was examined.
Results: Inflammatory pain was induced in rats by hindpaw injection of CFA and significantly increased phospho-ERK1/
2 positive cells and protein levels of p-ERK1/2 in the ipsilateral spinal cord dorsal horn (SCDH). CFA up-regulated of
cyclooxygenase-2 (COX-2) mRNA and protein expression at 6 h after injection and neurokinin-1 receptor (NK-1)
expression at 49 h post-injection, in the SCDH. EA, applied to Zusanli (ST36) and Kunlun (BL60), remarkably increased
the pain thresholds of CFA injected rats, significantly suppressed ERK1/2 activation and COX-2 protein expression after
a single treatment, and decreased NK-1 mRNA and protein expression at 49 h. EA decreased the DNA binding activity
of cAMP response element binding protein (CREB), a downstream transcription factor of ERK1/2, at 49 h after CFA
injection. Moreover, EA and U0126 synergistically inhibited CFA-induced allodynia.
Conclusions: The present study suggests that EA produces analgesic effect by preventing the activation of
ERK1/2-COX-2 pathway and ERK1/2-CREB-NK-1 pathway in CFA rats.
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Currently, inflammatory pain is one of the most serious
health problems worldwide. It is generally treated with
opioids and non-steroid anti-inflammatory drug (NSAID),
but both are limited by side effects [1]. Acupuncture has
long been used for the treatment of various diseases in* Correspondence: fangjianqiao7532@163.com
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alternative way of administering acupuncture, refers to the
application of a pulsating electrical current to acupuncture
needles for acupoint stimulation, and is a potential treat-
ment for inflammatory pain [2,3]. Although many studies,
including our own [4,5], showed that EA produced anti-
allodynia in patients and animal models of inflammatory
pain [6], the mechanisms of EA analgesia are still unclear.d. This is an Open Access article distributed under the terms of the Creative
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member of the mitogen-activated protein kinases (MAPKs)
family. Although the exact mechanism of inflammatory
pain is still unclear, there is mounting evidence demon-
strating MAPKs family play an important role in its
pathphysiology [7-10], especially ERK1/2 activated in
superficial dorsal horn [11]. It has been well demonstrated
that ERK1/2 regulates expressions of neurokinin-1 recep-
tors (NK-1) and cyclooxygenase-2 (COX-2) [12,13], two im-
portant mediators of inflammatory pain in central nervous
system [14,15], and thus contributed to altering sensitivity
to pain. In order to regulate gene expression, ERK1/2, as a
signaling molecule, must be translocated to the nucleus to
phosphorylate nuclear substrates such as Ets-like kinase 1
(Elk1) and cAMP response element binding protein (CREB)
[16,17]. These findings suggest that ERK1/2 signal pathway
(ERK1/2-Elk1/CREB-COX-2/NK-1) in the dorsal horn may
be a target for inflammatory pain treatment.
In previous study, we found that analgesic effect of
transcutaneous electrical nerve stimulation (TENS) on
inflammatory pain partly produced by modulating the
activation of the spinal ERK1/2 [18]. Our study also indi-
cated that EA’s analgesic effect was associated with the
inhibition of the activation of ERK1/2 in the spinal cord
dorsal horn (SCDH) in a rat inflammatory pain model [19].
Furthermore, ERK1/2 signal pathway has been regulated by
EA stimulation in central nerve system [20]. It has been
demonstrated that intracellular signal transduction path-
ways in spinal cord, such as p38 MAPK pathway [21],
have a crucial role in EA analgesia, however, few reports
detected that whether EA alleviated inflammatory pain by
modulating ERK signal transduction pathway activity in
the superficial spinal cord. Thus, we used a rat inflamma-
tory pain model to investigate the hypothesis that ERK
signal transduction pathway is involved in EA analgesia.
Methods
Animals
All animal care, surgery, and handling procedures approved
by the animal experiment centre attached to Zhejiang
Chinese Medical University were performed strictly in
accordance with the National Institutions of Health
Guide for the Care and Use of Laboratory Animals. Adult
Male Sprague–Dawley rats (200–230 g), used for this
study, were obtained from the animal experiment centre
attached to Zhejiang Chinese Medical University. They
were housed with artificial 12-h light–dark cycle lighting
with a controlled temperature (23 ± 1°C), and relative
humidity (70 ± 10%), and distilled water and food were
available ad libitum.
Experimental design
Two sets of experiments were conducted to investigate
the involvement of the ERK signal pathway in EA anti-allodynia: (I) EA regulated ERK signal pathway (II) EA
plus ERK antagonists. In experiment I, 200 rats were
randomly divided into four groups: (a) a control group
receiving normal saline (NS) injection, adminstered by
the same route and with the same volume as Complete
Freud’s Adjuvant (CFA, Sigma, USA) injection (n = 20);
(b) a model group receiving 100 μl CFA injection into
the plantar surface of the right hind paw (n = 60); (c)
an EA group receiving CFA injection and EA treatment
(n = 60) and (d) a sham EA group receiving CFA injection
and sham EA treatment (n = 60). At 6 h, 25 h and 49 h
after modeling, 20 rats of each group for model, EA
and sham EA were sacrificed to detecte the expression
of ERK1/2 and its downstream molecules by immuno-
histochemistry (n = 6), western blot (n = 6), real-time PCR
(n = 6) and electrophoretic mobility shift assay (EMSA)
(n = 2). Rats in control group were only sacrificed at
49 h after CFA injection. In experiment II, 30 rats were
injected with CFA and randomly divided into three groups:
(a) EA plus 10% dimethyl sulfoxide (DMSO) (n = 10); (b)
EA plus MEK (ERK kinase) inhibitor (U0126) in 10%
DMSO (n = 10); (c) 10% DMSO alone (n = 10). In both
experiments, 10 rats from each group were randomly
chosen for behavioral testing. After CFA injection, rats
were returned to their cage and allowed to recover.
Drug administration
For intrathecal drug delivery, a polyethylene-10 catheter
was implanted into the intrathecal space of the spinal
cord at the lumbar enlargement. The animals were allowed
to recover for 7 days after the operation before experimen-
tation. Rats were loosely immobilized by an assistant’ s
hands and 10 μl U0126 (1 μg; dissolved in 10% DMSO), as
previously described [12], was administrated at 5.5, 24.5
and 48.5 h after CFA injection. DMSO (10%, Abcam, UK)
was injected as a vehicle control.
Behavioral analysis
All pain behavioral testing was performed by a trained
investigator who was blinded to the experimental condi-
tions. Inflammatory allodynia was defined as a decrease
in paw withdrawal thresholds (PWTs) to a non-noxious
mechanical stimulus. PWTs were tested with an auto-
mated von Frey-type testing device (Dynamic Plantar
Aesthesiometer 37450, UGO Basile, Italy) as described
previously [21]. Rats received two training sessions before
the experiment started. Rats were placed on a metal mesh
table and adapted to the new environment for 30 min.
The mechanical stimulus was delivered to the plantar
surface of the right hind paw below the floor of the
plastic test chamber. A steel rod (diameter of 0.5 mm)
was pushed against the hind paw with ascending force.
The force went from 0 to 50 g over a 20 s period. When
the animal withdrew its hind paw, the mechanical
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which the rat withdrew its paw was recorded to the
nearest 0.1 g. In both experiments, the mechanical touch
sensitivity of paws were measured before modeling, and 5,
6, 25 and 49 h after CFA administration.
EA treatment
The EA or sham EA stimulation was applied at 5.5, 24.5
and 48.5 h after CFA injection. Rats were loosely immobi-
lized by an assistant’ s hands during the whole treatment.
Four stainless steel acupuncture needles of 0.25 mm in
diameter were inserted at a depth of 5 mm into the
bilateral “Zusanli” (ST36, between the tibia and fibula
5 mm below the knee) and “Kunlun” (BL60, 3 mm prox-
imal to the lateral malleolus) acupoints. The two ipsilateral
needles were connected to the output terminals of the
HANS Acupuncture point Nerve Stimulator (LH-202H,
Huawei Co., Ltd., Beijing, China). Electro-stimulation was
delivered with constant parameters, constant square wave
current output (pulse width: 0.6 ms at 2 Hz, 0.2 ms at
100 Hz); intensities ranging from 1–2 mA (each intensity
for 15 min, totaling 30 min); at 2 Hz and 100 Hz alternat-
ing frequencies (automatically shifting between 2 Hz and
100 Hz stimulation for 3 s each). Sham EA group animals
received the same subcutaneous needle insertion (2 mm
in depth) into ST36 and BL60, and the needles were
linked to the electrodes but without electrical stimulation.
To eliminate the stress effect, rats in the model and sham
EA groups were also loosely immobilized by an assistant’ s
hands similar to the EA group.
Immunohistochemistry
Rats were deeply anesthetized with 10% choral hydrate
(0.35 ml/100 g, intraperitoneal [i.p.]) and perfused through
the ascending aorta with saline, followed by 4% parafor-
maldehyde. Lumbar spinal cord (L4-L6) segments were
dissected and post-fixed for 6 h with the same fixative
solution. Transverse spinal cord sections (free floating,
30 μm) were cut and processed for immunohistochemistry
using the streptavidin-perosidase (SP) method. Briefly,
endogenous peroxidase activity was quenched with a
15 min incubation in 3% H2O2 at 37°C. Sections were
blocked with 5% goat serum plus 0.1% Triton X-100 for
1 h at 37°C and incubated overnight at 4°C with primary
antibody. The sections were then incubated for 1 h with
biotinylated secondary antibody (1:200) and 1 h with
horseradish peroxidase (HRP)-conjugated-avidin at 37°C.
Finally, the reaction product was visualized with diamino-
benzidine (DAB) in 0.1 M phosphate-buffered saline
(PBS) for 30 s. Sections were mounted on glass slides,
dehydrated through an ascending series of alcohol, cleared
with xylene, and coverslipped. Images were captured from
the ipsilateral dorsal horn at 20× magnification using a
Leica CCD camera. The following antibodies were used:anti-phospho-ERK1/2 (p-ERK1/2) (1:400, CST, USA)
and anti-phospho-Elk1 (p-Elk1) (1:400, CST, USA). Five
nonadjacent sections from the L4-L6 lumbar spinal cord
were randomly selected, and the numbers of immunoreac-
tive (IR) cells in the superficial lamina (lamina I-II) of the
dorsal horn in each section were counted by an observer
blind to the treatment. The mean values from the five
sections were determined for each animal.
Western blot
All rats were anesthetized with 10% choral hydrate
(0.35 ml/100 g, i.p.) and perfused transcardially with
150 ml cold sterilized saline. Ipsilateral spinal dorsal
horns (L4-L6) were removed and preserved at −80°C. For
western blot, the dorsal horns were homogenized with a
mechanical rotary cutter in strong RIPA buffer containing
a cocktail of phosphatase inhibitors and proteinase
inhibitors. The extracted protein was boiled in a sodium
dodecyl sulfate (SDS) sample buffer (100 mm Tris, pH 6.8,
2% SDS, 20% glycerol, 10% β-mercaptoethanol, and 0.1%
bromophenol blue). Protein samples were separated by
SDS-PAGE gel and transferred to nitrocellulose mem-
branes. The filters were blocked with 5% low-fat milk
and incubated overnight at 4°C with primary antibody.
Then the bolts were incubated for 1 h at 37°C with HRP-
conjugated secondary antibody (1:10,000) and visualized
in ECL solution (Thermo Scientific, USA) for 1 min and
exposed by the ImageQuant Las 4000 (General Electric
company). The band densities were quantified with a
computer-assisted imaging analysis system (Image Quant
software) and β-actin was used as an internal control.
The following primary antibodies were used: anti-
phospho-ERK1/2 (p-ERK1/2) (1:2000, CST, USA), anti-
COX-2 (1:1000, Caymen Chemical company, USA),
anti-NK-1 (1:1000, Millipore, USA), and anti-β-actin
(1:1000, CST, USA).
Real-time PCR
All rats were anesthetized with 10% choral hydrate
(0.35 ml/100 g, i.p.) and perfused transcardially with
150 ml cold sterilized saline. Ipsilateral spinal dorsal horns
(L4-L6) were removed and preserved at −80°C. Total
RNA was extracted using Trizol Reagent (Invitrogen,
France) by the guanidium thiocyanate method according
to the manufacturer’s instructions. RNA was quantified by
spectrophotometry. First strand cDNA was synthesized
from 1 μg of total RNA in a final volume of 10 μl using
the PrimerScript® RT reagent Kit with gDNA Eraser
(Takara, Japan). Relative mRNA levels were quantified by
RT-PCR using the fluorescent EvaGreen technology.
cDNA (1.5 μl) was subjected to real-time quantitative
PCR using the CFX96™ real-time PCR detection system
(Bio-Rad, USA). Primer premier 5.0 software (Premier,
Canada) was employed to design oligonucleotide primers
Figure 1 The paw withdrawal thresholds (PWTs) of rats in each
group at different time-points. PWTs were measured at pre-injection,
5, 6, 25 and 49 h after NS/CFA injections. Values represent mean ± SEM;
n = 10 per group for each time point. **P< 0.01 versus control group at
the corresponding time point. ▲▲P< 0.01 versus model group at the
corresponding time point. ##P < 0.01 versus sham EA group at the
corresponding time point.
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control). COX-2, forward: 5′-CACGGACTTGCTCACTT
TGTT-3′, reverse, 5′-AAGC GTTTGCGGTACTCATT-
3′; NK1, forward, 5′-CCACCAACACCTCTGAGTCTAA
CC-3′, reverse, 5′-GCCAGGTCCACCAGGAAATAA-3′;
GAPDH, forward, 5′-TGCTGAGTATGTCGTGG AG-3′,
reverse, 5′-GTCTTCTGA GTGGCAGTGAT-3′, with
product sizes of 161basic pairs (bp), 178 bp, and 288 bp,
respectively. Reactions (total volume, 20 μl) were incu-
bated at 95°C for 30 min, followed by 40 cycles of 10 s at
95°C and 30 s at 55.9°C (COX-2) or 59.0°C (NK-1). Water
controls were included to ensure specificity. Each sam-
ple was measured in triplicate, and data points were
examined for integrity by analysis of the amplification
plot. Adding the melting curve analysis in the reaction
condition, the analytical model: 65°C-95°C, an increase
of 0.5°C every 10 s. The comparative cycle threshold Ct
method was used for the relative quantification of gene
expression. The amount of COX-2 and NK-1 mRNA,
normalized to GAPDH and relative to a calibrator, was
given by 2-ΔΔCt, with Ct indicating the cycle number
at which the fluorescence signal of the PCR product
crosses an arbitrary threshold set within the exponential
phase of the PCR, and ΔΔCt = [(Cttarget (unknown sample)-
Ctend.control (unknown sample))]-[(Cttarget (calibrator sample)-
Ctend.control (calibra®or sample))].
Electrophoretic mobility shift assay
All rats were anesthetized with 10% choral hydrate (0.35
ml/100 g, i.p.) and perfused transcardially with 150 ml
cold sterilized saline. Ipsilateral spinal dorsal horns
(L4-L6) were removed and preserved at −80°C. Nuclear
protein was extracted from spinal cord dorsal horn
according to the manufacturer’s instructions of a Nuclear
Extract kit (Thermo Fisher Scientific, USA). For the CREB
promoter, the two complementary consensus oligonucleo-
tides were: 5′-AGAGATTGCCTGACGTCAGAGAGCT
AG-3′, 5′-CTAGCTCTTGACGTCAGGCAATCTCT-3′,
and the two complementary mutant oligonucleotides
were: 5′-AGAGATTGCCTGTGGTCAGAGAGCTAG-3′,
5′-CTAGCTCTCTGACCACAGGCAATCTCT-3′. Oli-
gonucleotides 3′- were labeled by biotin. To generate
double-stranded probes, biotin-labeled complementary
oligonucleotides were boiled for 5 min in 1 × sodium-
Tirs-EDTA buffer (STE, 10 mM Tris–HCl and 1 mM
EDTA, pH 8.0), then cooled slowly to room temperature
overnight. Unlabeled complementary oligonucleotide
pairs were annealed to make double-stranded competi-
tor probes. EMSA was performed using a Light Shift
Cheniluminescent EMSA kit (Thermo Fisher Scientific,
USA). Ten μg of unclear protein from each sample was
incubated with a biotinylated probe in the reaction
buffer for 30 min at room temperature (RT). Then the
reaction mixture was subjected to 6% non-denaturingpolyacrylamide gel electrophoresis, and transferred to
Nylon membranes. Biotin-labeled DNA was detected
using a streptavidin-horseradish peroxidase conjugate
and chemiluminescent ECL kit (Thermo Fisher Scientific,
USA). The images were captured by ImageQuant Las
4000 and analyzed using ImageQuant software. A compe-
tition EMSA was performed by adding 100× molar excess
of unlabeled doubled-stranded oligonucleotide.
Quantification and statistics
Differences between groups were compared using stu-
dent’s t-test or ANOVA, followed by least significant
difference (LSD) test. The data were represented as
mean ± standard error mean (SEM). The PWTs data
were normally distributed, and were therefore analyzed
using a repeated-measures analysis of variance (ANOVA)
with between-subjects factors. The density of specific
bands of western blotting was quantified by densitometric
scanning analysis. The criterion for statistical significance
was P < 0.05.
Results
Effect of EA on inflammatory pain hypersensitivity in
CFA rats
Mean PWTs in all experimental groups at each time
point are shown in Figure 1. The repeated-measures
ANOVA with between-subjects factors revealed differences
over time points (P < 0.01) and between groups (P < 0.01).
There were significant interactive effects between time
points and groups (P < 0.01). Post-hoc LSD tests indicated
that CFA injection caused decreased PWTs in rats
(P < 0.01). Sham EA treatment did not change rat PWTs
compared with the model group (P > 0.05). A significant
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compared with the model group (P < 0.01) and the sham
EA group (P < 0.01). However, PWTs in the EA group still
showed a significant difference compared with those of
the control group (P < 0.01).
To compare PWTs between groups at different time
points, model and sham EA groups were combined because
there was no significant difference in PWTs between them.
One-way ANOVA for independent samples identified
that significant differences occurred among controls,
EA and combined groups from 6 h to 49 h after CFA
injection (P < 0.01). Compared with the control group,
plantar injection of CFA to the right hind paw signifi-
cantly decreased the mechanical threshold during the
observed time points (P < 0.01). Following EA treatment,
PWTs of rats in the EA group were significantly increased
compared with those in the model and sham EA group
from 6 h to 49 h (P < 0.01). However, at 49 h after CFA
injection, a significant difference in PWTs was still
observed between the EA and control groups (P < 0.01).
P-ERK1/2, COX-2 and NK-1 induction by peripheral
inflammation
As shown in Figure 2A-D, peripheral inflammation induced
by CFA injection resulted in the activation of ERK1/2
in the superficial dorsal horn on the ipsilateral side of
the lumbar enlargement. The numbers of phospho-ERK1/
2 (p-ERK1/2)-IR cells were increased from 6 h to 49 h
after CFA injection (P < 0.01) (Figure 2E). We further
investigated the expressions of COX-2 and NK-1 mRNA,
two commonly detected markers of pain conditions in a
variety of pain models [22,23], at different time points.
Real-time PCR was used to measure their expression
in response to intraplantar CFA injection. The over-
expression of COX-2 mRNA in SCDH was only detected
at 6 h after CFA treatment (P < 0.01) (Figure 2F), and a
mild up-regulation of COX-2 mRNA in SCDH was
detected at 25 and 49 h after CFA injection (P > 0.05).
In contrast to COX-2 mRNA expression, CFA injection
significantly increased NK-1 mRNA expression only at
49 h after CFA injection (P < 0.01) (Figure 2G).
Effect of EA on ERK1/2 activation in the lumbar spinal cord
Based on the above findings, we tested the effect of EA
on ERK1/2 activation at 6 and 49 h after CFA injection
using immunohistochemistry. The CFA-evoked increase
of numbers of p-ERK1/2-IR cells in the superficial SCDH
was suppressed by EA treatment at 6 h and 49 h after
CFA injection (P < 0.01) (Figure 3A-E). We also investi-
gated the effect of EA on p-ERK1/2 protein expression at
6 and 49 h according to the over-expressing time points of
COX-2 and NK-1. Different with the immunohistochem-
istry results (Figure 2E), p-ERK1/2 protein was not highly
expressed at 49 h after CFA injection, compared with thecontrol level (Figure 3G). Compared with the model
group, EA only reduced CFA-increased p-ERK1/2 protein
levels in the ipsilateral dorsal horn at 6 h after CFA-
injection (P < 0.01) (Figure 3F-G). Sham EA administra-
tion did not affect either the number of labeled cells or
p-ERK1/2 protein expression at 6 h and 49 h, when
compared with the model group (P > 0.05, Figure 3).
Effect of EA on COX-2 expression
To investigate whether EA could regulate COX-2 expres-
sion, we used both real-time PCR and western blot to
measure the COX-2 mRNA and protein at 6 h after CFA
treatment. Both COX-2 mRNA and protein expression in
SCDH significantly increased at 6 h after CFA injection,
compared with the control group (P < 0.01). No significant
difference in COX-2 mRNA expression was observed at
6 h after CFA injection (P > 0.05) between the model, EA
and sham EA groups (Figure 4A). However, EA treatment
significantly inhibited CFA-induced over-expression of
COX-2 protein (P < 0.01), while sham EA treatment
did not show any inhibitory effect on COX-2 protein
(P < 0.01) (Figure 4B).
Effect of EA on NK-1 expression
Since NK-1 was over-expressed in SCDH at 49 h after
CFA injection, the regulating effect of EA on NK-1 expres-
sion in SCDH was assessed by real-time PCR and western
blot at this time point. Compared with the control group,
expression level of NK-1 mRNA and protein in SCDH
was significantly increased in the model group (P < 0.01).
EA treatment significantly down-regulated the expres-
sion of NK-1 mRNA, compared with the control group
(P < 0.01, Figure 5A). Similarly, EA also suppressed the
CFA-induced increase of NK-1 protein expression in
SCDH (P < 0.05, Figure 5B-C). Sham EA produced no
inhibitory effect on NK-1 mRNA or protein expression
(P > 0.05) (Figure 5).
Peripheral inflammation has no effect on Elk1 expression
Elk1 is a well-characterized downstream nuclear substrate
of ERK1/2 and p-Elk1 tend to move into the nucleus to
regulate target transcription factors. Since our study
suggested a role for EA in inhibiting p-ERK1/2, COX-2
and NK-1 mRNA expression in CFA rats, the expression
of p-Elk1 was measured in SCDH at each time point.
However, the numbers of p-Elk1-IR cells in the model
group were unaffected at each time point compared with
the control group (P > 0.05) (Figure 6).
Effect of EA on CREB combination
Since our study suggested a role for EA in inhibiting
COX-2 and NK-1 expression in CFA rats, the nuclear
extracts from SCDH of rats in the control, model, EA
and sham EA groups at 6 and 49 h after CFA injection
Figure 2 The expressions of p-ERK1/2-IR cells, COX-2 mRNA and NK-1mRNA in spinal cord dorsal horn of rats in control group and at
6, 25 and 49 h after subcutaneous injection of CFA into the plantar hindpaw region. A-D. Immunohistochemistry shows p-ERK1/2-IR cells
in the L4-6 ipsilateral spinal cord dorsal horn in control rats (A), model rats at 6 h (B), 25 h (C), and 49 h (D). E-G. Quantification of p-ERK1/2-IR
cells, COX-2 mRNA and NK-1 mRNA expression in L4-6 ipsilateral spinal cord dorsal horn, respectively. Results are mean ± SEM; n = 6. *P < 0.05,
**P < 0.01 versus control group at the corresponding time point. The scale bar is 100 μm.
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group did not contain appreciable levels of CREB-
binding (Figure 7A, lane 2), whereas nuclear extracts
from the model, EA and sham EA groups bound very
efficiently to a CREB consensus probe (Figure 7A, lanes
3–8). In addition, the binding ability in the EA group at
49 h was weaker than that observed in the model and
sham EA groups at the same time point (Figure 7A,
lane 7). To check the specificity of the protein-DNA
interactions, competitive EMSA was performed, using
100× molar excess of unlabeled doubled-stranded oligo-
nucleotide CREB probe (unlabeled p-CREB) and unlabeled
mutant doubled-stranded oligonucleotide CREB probe
(unlabeled p-CREBm) added as a competitor for the
respective treatments. No CREB binding to the target
DNA was observed in the competitive assay of unlabeled
p-CREB probe (Figure 7B, lane3) and weak binding was
observed in the competitive assay using an unlabeledp-CREBm probe (Figure 7B, lane4). Similarly, biotin-
labeled mutant doubled-stranded oligonucleotide CREB
probe (biotin-labeled p-CREBm) was used to check the
specificity of protein-DNA interactions. No binding was
observed in the assay (Figure 7B, lane5).Analgesic effect of electroacupuncture plus U0126 on
inflammatory pain
To elucidate whether ERK1/2 is involved in the analgesic
effect of EA, U0126, a MEK inhibitor, was delivered
intrathecally with EA treatment at 5, 24 and 48 h after
CFA injection. As described above, the repeated-measures
ANOVA with between-subjects factors also revealed
differences over time points (P < 0.01) and between groups
(P < 0.01). Post-hoc LSD tests indicated that, after CFA
injection, both the administration of EA + DMSO and
EA + U0126 increased rat PWTs compared with DMSO
Figure 3 Effect of EA on p-ERK1/2 expression in the spinal cord dorsal horn in inflammatory pain. Immunohistochemiscal analysis shows
p-ERK1/2-IR cells in the L4-6 ipsilateral spinal cord dorsal horn in control rats (A), model rats (B), EA-treated rats (C) and sham EA-treated rats (D) at 6 h after
CFA injection. (E). Quantification of p-ERK1/2-IR cells in the L4-6 ipsilateral spinal cord dorsal horn of the control group and at 6 and 49 h after CFA injection.
(F). The expression of p-ERK1/2 protein in the L4-6 ipsilateral spinal cord dorsal horn by western blot. (G). The quantification of p-ERK1/2 protein normalized
against β-actin. Results are mean ± SEM; n = 6. **P< 0.01 versus control group at the corresponding time point. ▲P< 0.05, ▲▲P< 0.01 versus model group
at the corresponding time point. ##P< 0.01 versus sham EA group at the corresponding time point. The scale bar is 100 μm.
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EA + U0126 group showed a significant increase com-
pared with the EA + DMSO group (P < 0.01).
One-way ANOVA for independent samples identified
significant differences occurred between the DMSO,
EA +DMSO and EA +U0126 groups from 6 to 49 h after
CFA injection (P < 0.01). Administration of EA +DMSO
increased the mechanical PWTs from 6 to 49 h after CFA
injection compared to with the DMSO control group
(p < 0.01). Moreover, the analgesic effect elicited by co-
treatment of EA and U0126 was significantly stronger
in mechanical allodynia at 6, 25 and 49 h after model-
ing when compared with EA or DMSO alone (P < 0.01)
(Figure 8).Discussion
Although early studies of ERK1/2 focused on its relation
with mitosis, proliferation and differentiation of cells [24],
a growing body of evidence suggests that ERK1/2 activa-
tion contributes to pain hypersensitivity [25]. Especially,
ERK1/2 activation in SCDH plays a key role in developing
and maintaining mechanical allodynia induced by periph-
eral inflammation [26-29]. In the present study, p-ERK1/2
positive cells in the ipsilateral side of SCDH significantly
increased during the developmental phase (6 to 49 h after
CFA injection) of inflammatory pain-related hypersensitiv-
ity, consistent with published data from previous studies
[12,26]. However, results from western blot showed p-
ERK1/2 protein only increased at the 6 h after CFA
Figure 4 Effect of EA on COX-2 expression in the ipsilateral spinal
dorsal horn at 6 h after CFA injection. (A). The expression of COX-2
mRNA (relative to GAPDH) in L4-6 ipsilateral spinal dorsal horn was
measured by real-time PCR. **P < 0.01 versus control group. ▲P < 0.05
versus model group. #P < 0.05 versus sham EA group. Results are
mean ± SEM; n = 6. (B). The expression of COX-2 protein measured by
western blotting analysis. **P < 0.01 versus control group. ▲P < 0.05
versus model group. #P < 0.05 versus sham EA group. Results are
mean ± SEM; n = 6. (C). COX-2 protein in normalized against β-actin.
Figure 5 Effect of EA on NK-1 expression in the ipsilateral spinal
dorsal horn at 49 h after CFA injection. (A). The expression of NK-1
mRNA (relative to GAPDH) in L4-6 ipsilateral spinal dorsal horn measured
by real-time PCR. **P< 0.01 versus control group. ▲▲P< 0.01 versus
model group. ##P< 0.05 versus sham EA group. Results are mean ± SEM;
n = 6. (B). The expressions of NK-1 protein in the L4-6 ipsilateral spinal
cord dorsal horn by western blotting analysis. **P< 0.01 versus control
group. ▲P< 0.05 versus model group. Results are mea n ± SEM; n = 6.
C. NK-1 protein in normalized against β-actin.
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superficial dorsal horn (laminae I-II), western blot may
be less sensitive and accuracy than immunohistochem-
istry in detecting ERK activation in such small subset of
SCDH, and the result that the number of p-ERK1/2
positive cells at 49 h is much lesser than at 6 h after
CFA injection may confirm this conjecture. Some
reports revealed ERK1/2 activation could regulate the
expression level of COX-2 and NK-1 [12,13], two well-
characterized mediators of pain, we investigated their
expression further. COX-2 has been thought to contrib-
ute to inflammatory pain for many years [23,30]. Our
results showed that CFA induced mechanical allodyniaand an increase in COX-2 protein and mRNA expression
on the ipsilateral side of the SCDH at 6 h after injection.
These mechanisms might allow COX-2 to perform as a
central component of inflammatory pain hypersensitivity
in neurons of the central nervous system by increasing
neuronal excitation and reducing neuronal inhibition [31].
Several evidence also suggested that NK-1 in the SCDH
played an important role in inflammatory pain hypersensi-
tivity [32]. The amount and internalization of NK-1 recep-
tors on SCDH neuron densities increased after peripheral
inflammation [33], and induced mechanical allodynia in
several inflammatory pain models [34,35]. In agreement
with previous studies [12,36], peripheral inflammation
Figure 6 The expression of p-Elk1-IR cells in spinal cord dorsal horn of rats in the control group and at 6, 25 and 49 h after subcutaneous
injection of CFA into the plantar hind paw region. A-D. Immunohistochemical analysis shows p-Elk1-IR cells in the L4-6 ipsilateral spinal cord dorsal
horn of control rats (A), model rats at 6 h (B), 25 h (C) and 49 h (D). E. Quantification of p-Elk1-IR cells in L4-6 ipsilateral spinal cord dorsal horn,
respectively. Results are mean ± SEM; n = 6. *P < 0.05, **P < 0.01 versus control group at the corresponding time point. The scale bar is 100 μm.
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after CFA injection. Taken together, we hypothesized that
ERK1/2 activation after peripheral inflammation resulted
in pain hypersensitivity by inducing different protein
expression at different time points in CFA rats. Activated
ERK1/2 induced COX-2 expression at 6 h after CFAFigure 7 Effect of EA on p-CREB DNA binding activity in L4-6 ipsilater
to CREB probe in nuclear extracts prepared from control and model, EA, an
CREB in the control group was considered for comparison (lane 2). EA regu
(B). EMSA experiment showing the binding of proteins present in the nucl
Specificity of the DNA-protein interaction was assessed by competition EMSA u
CREB probe (lane 3), unlabeled mutant doubled-stranded oligonucleotide
oligonucleotide CREB probe (lane 5).injection and NK-1 expression at 49 h after CFA injection.
However, we did not observe either COX-2 or NK-1 over-
expressions at 25 h after CFA treatment. The reason for
this is not clear and requires further study.
EA treatment has been shown to have analgesic effects
in various pain models [37-41]. In the present study, EAal spinal cord dorsal horn. (A). EMSA experiment showing binding
d sham EA groups at 6 and 49 h after CFA injection. The binding of
lated CREB protein binding activity at 49 after CFA-treated (lane 7).
ear extracts prepared from the model group at 49 h after CFA injection.
sing a 100× molar excess of unlabeled doubled-stranded oligonucleotide
CREB probe (lane 4) and biotin-labeled mutant doubled-stranded
Figure 8 Effect of MEK inhibitor (U0126) on PWTs to mechanical
stimuli in CFA-injected rats with EA stimulation. PWTs were
measured at pre-injection, 5, 6, 25 and 49 h after CFA injection. Values
represent mean ± SEM; n = 10 per group for each time point. ○○P <
0.01 versus DMSO group at the corresponding time point. △△P < 0.01
versus EA plus DMSO group at the corresponding time point.
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(6 h after CFA injection) and maintained the analgesic
effect by repeated administration during the whole study
period. Moreover, in addition to the analgesic effect, EA
treatment significantly inhibited ERK1/2 activation in
SCDH. These results, similar as we reported before [19],
delineated the crucial role of ERK1/2 in the analgesic
effect of EA. Since TENS, mostly thought has the same
mechanism with EA, produced analgesic effect by regu-
lated ERK1/2 signaling pathway, we further investigated
EA’s effect on the downstream substance of ERK1/2
[18]. Previous studies demonstrated that EA treatment
produced anti-inflammatory pain effects through the
regulation of COX-2 and NK-1 expression in both
peripheral and central nociceptive sites, which were
induced by peripheral inflammation [42-44]. Along with
the change of ERK1/2 activation levels, EA significantly
suppressed COX-2 protein expression, but not COX-2
mRNA expression at 6 h after CFA injection. It is gener-
ally thought that effects produced by transcriptional
regulation should take a relatively long of time [12]. In
this experiment, the therapeutic effect produced by
inhibiting ERK1/2 activation might be too quick (<1 h) to
be mediated by the inhibition of transcription and there-
fore it likely represented a post-translational change of
ERK1/2, similar as previous study [11]. So, the analgesic
effect of EA might be partly produced by regulating post-
translational changes. On the other hand, the effect of
EA on NK-1 expression was detected. Different to the
regulatory effects on COX-2, EA prevented increased
expression of NK-1 mRNA and protein in SCDH at
49 h after CFA injection. Since EA regulated p-ERK1/2
and NK-1 in a time-dependent way, we hypothesizedthat the EA analgesic effect was also produced by regulating
transcription changes. Thus, EA treatment may regulate
ERK1/2-COX-2 protein at 6 h after CFA injection and
ERK1/2-NK-1 mRNA/protein at 49 h after CFA injection.
Activated ERK1/2, an intracellular signaling molecule, is
translocated to the nucleus to phosphorylate downstream
nuclear substrates such as Elk1 [16,45]. A previous study
demonstrated that Elk1 formed an important link in the
ERK pathway to transduce signals from the cell surface to
the nucleus for the activation of genetic machinery neces-
sary to maintain synaptic plasticity [46]. Synaptic plasticity
is regarded as the foundation of central sensitization and
pain. However, we did not observe a difference in p-Elk1
expression between the control and model groups at any
time point studied. This indicated that ERK1/2 might not
regulate gene transcription via activating Elk1 in SCDH in
CFA rats.
We also tested the DNA binding activity of CREB, an-
other downstream transcriptional target of activated ERK1/
2. Noxious stimulation and peripheral inflammation evoked
CREB activation in the dorsal horn [47]. Similarly, we found
the DNA binding activity of CREB was up-regulated by
peripheral inflammation at 6 and 49 h after CFA injection.
EA treatment significantly down-regulated the DNA bind-
ing activity of CREB at 49 h after CFA injection, but not at
6 h. Since several studies demonstrated phospho-CREB
(p-CREB) could transactivate COX-2 and NK-1 promoters
[48,49], ERK1/2 activation might contribute to inflamma-
tory pain by the ERK1/2-CREB-NK-1 pathways in SCDH.
This result is compatible with the above findings that
EA alleviated inflammatory pain by post-translational
regulation at 6 h and by transcriptional regulation at 49 h.
Therefore, inhibition of ERK1/2-COX-2 pathway activation
by post-translational regulation and ERK1/2-CREB-NK-1
pathway activation by transcriptional regulation may be
two potential methods to alleviate persistent inflammatory
pain by EA.
Since we previously demonstrated that EA regulate
p38 MAPK pathway in the SCDH of inflammatory rats
[21], and p-ERK1/2 was only partially inhibited by EA
from the present finding, ERK pathway cannot be the
only signal transduction pathway under EA analgesia. To
confirm this, the effect of a MEK inhibitor administrated
by intra-thecal injection, on CFA-induced hyperalgesic
behavior was performed. EA plus U0126 showed a syn-
ergistic effect on antinociception against inflammatory
pain. So EA alleviated inflammatory pain partly due to
the regulation of ERK pathway in SCDH. There was a
big difference of PWT between Figures 1 and 8. The
main reason may be attributed to the conditions of rats,
which were put into use in two parts of experiment, used
in different batches, feed in different climates and tested
in different rooms (though the temperatures being strictly
controlled). The operation implanted the polyethylene-10
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be the second reason. However, the injection of CFA also
induced a significant inflammatory pain, so we thought
the results of Figure 8 are credible.
Conclusions
In summary, the present study shows EA treatment might
be a useful therapy for the treatment of inflammatory pain
allodynia. This analgesic effect may be associated with
inhibition of ERK pathway activation in SCDH. Since acti-
vated ERK1/2 up-regulated COX-2 and NK-1 at different
time points, different mechanisms exist in the mechanism
of EA-induced analgesia, including post-translational
regulation-induced inhibition of ERK1/2-COX-2 pathway
activation, or transcriptional regulation-induced inhibition
of ERK1/2-CREB-NK-1 pathway activation.
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